Clinical Trials
6 trialsNCT05508867 2026-01-20
MK-4280A-008
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT02927769 2025-02-10
CheckMate 744
Bristol-Myers Squibb
Phase 2 Completed
NCT01716806 2024-06-11
A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)
Seagen Inc.
Phase 2 Completed
NCT02733042 2023-11-18
FUSION NHL 001
Celgene
Phase 1/2 Completed
NCT04268706 2023-04-05
Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT)
Tessa Therapeutics
Phase 2 Active not recruiting
NCT01874054 2019-02-12
Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma
Seagen Inc.
Phase 1/2 Completed